Patients diagnosed with mesothelioma often face a difficult decision, should they undergo treatment and possibly suffer side effects and hopefully have longer with their loved ones, or elect to receive palliative treatment?
A study out of Madrid’s 12 de Octubre University Hospital has been looking at a new potential first-line treatment, ONCOS-102 and the results are encouraging.
Clinical trial for pleural mesothelioma
The trial, conducted in Spain, is treating malignant pleural mesothelioma patients with a combination of ONCOS-102 and pemetrexed/cisplatin chemotherapy, the most commonly used treatment for mesothelioma.
Patients treated with the combination including ONCOS-102 were compared to patients who received the pemetrexed/cisplatin chemotherapy only. The results showed that those who had ONCOS-102 had progression free survival for nine months after treatment.
Step forward for mesothelioma patients
Sadly, there is still no known cure for mesothelioma however, a treatment that can prevent progression of the disease is a huge step forward for those suffering with the condition.
The lead researcher, Luis G Paz-Ares was pleased with the trial, statingl; “Although the data are preliminary and still maturing, it is encouraging to see signals of numerically improved median PFS in the ONCOS-102-treated group.”
We hope that researchers are able to continue to make progress in the treatment of mesothelioma and one day a cure can be found.
If you require assistance in pursuing an asbestos compensation claim for mesothelioma or any other asbestos-related disease, then please contact us today on our freephone number 0800 038 6767. Alternatively, head over to the ‘Contact Us’ page, complete the form and we will be in touch.
Targovax releases update for mesothelioma trial combining ONCOS-102 and chemotherapy [news release]. Oslo, Norway: Targovax ASA; May 4, 2020. https://bit.ly/2WsFwmM. Accessed May 5, 2020.
Targovax announces encouraging data in mesothelioma study combining ONCOS-102 and standard of care chemotherapy [news release]. Oslo, Norway: Targovax ASA; January 21, 2020. https://bit.ly/3c9nahk. Accessed May 5, 2020.